Very good find.Yes,she was.

you are welcome.

Also look at the positive references for LindaPowers in LinkedIn. Topline results in September $$$$$$

https://www.uclahealth.org/neurosurgery/braintumor-brad-silver

Could anybody provide me a link or summary of the new SAP?

IBM is collaborating!Study completion in August!
Jackpot!!! Please spread the word on all message boards.

https://clinicaltrials.gov/ct2/show/NCT04311697?term=aviptadil&draw=2&rank=1

How much do you think the company will be worth if RLF-100 gets approved?

"VIP is the only pulmonary therapeutic to have been granted Fast Track status by the US FDA and to be allowed into both phase 2/3 clinical trials, as well as an expanded use protocol for those who are unable to enter the clinical trial because of excluded comorbidity."

"Although the FDA phase 2/3 clinical trials remain blinded, some patients have been treated under open label Emergency Use IND on a named-patient basis. Rapid clearing of pneumonitis has been documented on radiography (Figure 1) with concurrent improvement in oxygenation and patient transition from intensive care with mechanical ventilation to home discharge on room air within days of IV infusion."
https://www.authorea.com/users/321659/articles/472151-vasoactive-intestinal-peptide-treats-respiratory-failure-in-covid-19-by-rescuing-the-alveolar-type-ii-cell

Next step is conditional approval.
https://authorea.com/users/321659/articles/472197-neurorx-expanded-access-protocol-rlf-100-ea-1-v1-0

No

Market cap target $1b-->$5b if neubulizing works so you can use it at home!

Extremely bullish news: no more debt! only 10% discount means that these guys know that the stock is currently criminally undervalued. Let´s go to $0.5-$1/share

https://relieftherapeutics.com/relief-therapeutics-holding-sa-to-agree-share-settlement-for-an-outstanding-chf-1723300-debt-position-provided-by-gem/

Word is getting out. https://spectrumnews1.com/ky/lexington/news/2020/07/16/uofl-clinical-trials-covid19-coronavirus-treatment

Jackpot news: "NeuroRx and Relief Therapeutics Announce Data Monitoring Committee Determination to Continue Phase 2/3 Trial of RLF-100 for Critical COVID-19" https://www.globenewswire.com/news-release/2020/07/16/2063002/0/en/NeuroRx-and-Relief-Therapeutics-Announce-Data-Monitoring-Committee-Determination-to-Continue-Phase-2-3-Trial-of-RLF-100-for-Critical-COVID-19.html

Ye$$$$$

Last 4 recent Management Transactions were all purchases:

03.07.2020 RELIEF THERAPEUTICS Holding SA Purchase Registered shares 145'655 CHF 5'080.90

03.07.2020 RELIEF THERAPEUTICS Holding SA Purchase Registered shares 125'000 CHF 4'800.00

30.06.2020 RELIEF THERAPEUTICS Holding SA Purchase Registered shares 2'500'000 CHF25'000.00

29.06.2020 RELIEF THERAPEUTICS Holding SA Purchase Registered shares 298'356 CHF 10'502.13

https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/

I don´t like OTC stocks and the word "believe". Climb is done.

Ok. Thanks

Ok.

I expect an immediate buyout after positive P3 results from Merck for 5 billion dollar or $6-7/share

5 billion dollar for DCVax-L alone, but because of DCVax-direct: 8 billion dollar.

Look at LindaPowers LinkedIn page:look at all acknowledgements from all highly-respected professionals in the medical field.

Rougly speaking based on 670 million outstanding shares

Very good that no warrants can be exercised before november. So the share price has sufficient room to move on positive P3 results, the acceptance from all regulatory agencies to accept and give the exact timeline to judge on commercial use, and release the news for partnerships and/or buyout.
No room for naked shorts till November.
PT on positive P3 results = $3-5/share or a MC of $2b-3,4b
Because of filing for commercial approval in the US,Canada and entire Europe. Because of higher possibilities of success for DcVax direct. And because it is very attractive to combine with other cancer treatments from big pharma companies.
My guess:
NWBO will be bought by Merck or BMS
CVM will be bought by TEVA

"Mrs Powers, we want to buy your company and you may remain the director of the DCVax-programm as our new subsidiary". Considering the positive outcome from your phase 3 results for ndGBM we want to offer the price of $5b dollar" (hehe, normally we wanted to pay $15b, but thanks to naked short we can pay $5b).
"Ok, Mr Duffy, tell you company BMS I agree. Share price $6,5/share. Where do I sign?"

I am sorry that you just don´t understand the meaning of changes in SAP.

But it can be replaced to "additional endpoints" since PFS is not a good indicator in immunotherapy as observed in Keytruda.

Me too.

Am I correct that since the FDA agreed with the changes in the SAP that the endpoint now is more in the direction of OS instead of PFS and mOS?

PT on positive P3 -taking into account it has the potential for worldwide approval?

I think DFFN will be the number one stock for 2020. 86% survival at two years for inoperable GBM versus 13% in SOC in an open label study and 4x better overall survival in phase 2 vs historical data.
That is really extraordinary.

“Diffusion Pharmaceuticals Presents Data Suggesting Optimized TSC Dosing Regimen Increases Survival in Newly Diagnosed Inoperable Glioblastoma Patients”
https://diffusionpharma.com

That is a big wild card! If approved PT short term will be between $3-$5/share or $66m-$110 m market cap

Lots of big companies attending here like:
Roche-Genentech MC $257b
Novocure MC $7b
AstraZeneca MC $124b
Abbvie MC $128b

You can bet they will attend NWBO’s presentation as well, because it’s nearing P3 completion. All buyout candidates for NWBO.

Nope, that’s around 12h30-13h00 usually. Like is in here: lunch at 12h40. I attend a lot of medical congresses for my job. Oncologists have high expectations about dendritic vaccines. DCVax-L works on all biomarkers and works on the entire immune system. This could be the Greatest LEAP in immune therapy so far.

“11:40 am DCVax Technology: Leveraging Activated Dentritic Cells in Clinical 40 for GBM

Marnix Bosch
CTO, Northwest Biotherapeutics
Synopsis

Exploring the history, biology and development of the platform technology DCVax
Outlining the key aspects of the DCVax technology that contribute to the positive clinical results
Designed to mobilize the ENTIRE immune system
Designed to target not just one but the full set of biomarkers on the patient’s tumor
DCVax is personalized, and targets the particular biomarkers expressed on that patient’s tumor
Pinpointing highs and lows of clinical development to date”

https://glioblastoma-drugdevelopment.com/about/agenda/day-two/

I wonder what Marnix Bosch is going to present here:
Boston, December 10-11 Time: 11:40 am - Day: Day Two Speakers: Marnix Bosch
DCVax Technology: Leveraging Activated Dentritic Cells in Clinical for GBM

https://glioblastoma-drugdevelopment.com

The second day at a congress right before noon, that’s usually when the most important topics of the congress are being presented.

Boston, December 10-11 Time: 11:40 am - Day: Day Two Speakers: Marnix Bosch
DCVax Technology: Leveraging Activated Dentritic Cells in Clinical for GBM

https://glioblastoma-drugdevelopment.com

All pieces are coming together.

I agree. Duffy is doing a great job, taking care for the SAP AND later on FDA/EMA approval+buyout by Merck for +$10b.

I have the feeling we will get extraordinary good results for DCVax-L.